Pure Life Healthcare Management Announces Acquisition of Revolution Medical Cannabis Clinic

Pure Life Healthcare Management Announces Acquisition of Revolution Medical Cannabis Clinic


Pure Life Healthcare Management (PLHM), an integrated wrap-around healthcare provider today announced the successful acquisition of Revolution Medical Cannabis (RMC), a prominent virtual clinic specializing in the delivery of medical Cannabis for the Canadian market. This strategic acquisition further solidifies PLHM's commitment to revolutionizing healthcare delivery and expanding its digital footprint in the telehealth sector.

RMC has built an impressive network of doctors providing top-tier virtual care to thousands of patients across the country with its state-of-the-art platform. By integrating RMC's unique offerings, PLHM aims to enhance its current services and provide a more comprehensive and seamless patient experience.

"As we continue our journey to redefine healthcare in the digital age, the acquisition of Revolution represents a significant step with our vision to lead the digital transformation of healthcare. Their expertise and technological capabilities will not only complement our current services but also enable us to reach more patients in innovative ways. Together, we will set new standards for virtual healthcare delivery, ensuring that every patient, no matter where they are, has access to quality care right at their fingertips."

- Doug Page, CEO of PLHM

Integrating the two companies will combine technological resources, streamline virtual consultations, and ensure faster, more reliable access to medical professionals. Existing patients of RMC can expect a smooth transition with continued excellence in care and a host of enhanced features in the near future.

About Pure Life Healthcare Management

Pure Life Healthcare Management is a company dedicated to providing comprehensive support for individuals dealing with trauma, including PTSD. With a specific focus on veterans, first responders, and front-line healthcare workers, PLHM is poised to be the first national network of wrap-around medical facilities focusing on treating trauma. The company adopts a holistic approach that integrates mental, physical, and emotional support, demonstrating a commitment to addressing the various aspects of healing and recovery.

About Revolution Medical Cannabis

Revolution Medical Cannabis was founded with a deep commitment to bridging healthcare gaps and is a pioneering virtual clinic catering to the distinct needs of clients across the country. With an extensive network of top-tier doctors and medical professionals, RMC specializes in delivering timely, efficient, and tailored healthcare solutions. Their reach extends Canada-wide, ensuring not only expert consultations but also doorstep delivery of prescribed medications, embodying our vision of comprehensive and accessible healthcare for all.

For more information, please contact:
Doug Page, CEO
1 888 454 4144
IR@plhm.ca

Cautionary Statement About Forward-Looking Information:

This document contains statements that may constitute forward-looking information under applicable securities legislation. Such forward-looking information can often, but not always, be identified by the use of words like "anticipates", "believes", "estimates", "projects", "potential", "plans", "seeks", or statements that events, conditions, or results "will", "may", "could" or "should" occur or be achieved, and other similar expressions. These statements reflect management's current beliefs and are based on information currently available to management. Forward-looking information involves risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information.

Factors that could cause actual results to differ materially from these forward-looking statements include those risks set out in the Company's public documents filed on national securities websites in the country of incorporation. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this document are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this document, and no assurance can be given that such events will occur. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable law.

Click here to connect with Pure Life Healthcare Management (PLHM) to receive an Investor Presentation

Source

The Conversation (0)

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

  • Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation
  • Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events
  • Vepdegestrant is the first and only   PROteolysis TArgeting Chimera   (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
  • Data to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of Medicine
  • Arvinas will host a conference call to discuss these results on Monday, June 2, at 8:00 a.m. ET

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 46 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology (ASCO ® ) press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation (Abstract LBA1000) and have been simultaneously published in the New England Journal of Medicine .

Keep reading...Show less

Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

  • Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment
  • BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease progression or death compared to standard-of-care treatment, meeting the trial's dual primary endpoint of progression-free survival
  • First and only combination regimen with targeted therapy to improve survival outcomes for treatment-naïve patients with BRAF V600E-mutant metastatic colorectal cancer

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ® ) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These data will be presented today in an oral presentation (Abstract LBA3500) at the 2025 American Society of Clinical Oncology (ASCO ® ) Annual Meeting and have been simultaneously published in the New England Journal of Medicine .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Hearing Against Pfizer Set For 30 May In Contraceptive 'Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio

  • Global pharmaceutical company Pfizer Inc. is facing a multidistrict litigation (MDL No.3140) in the USA, currently comprising approximately 400 lawsuits against the company.
  • This MDL follows a study by EPI-PHARE (Roland et al.) published in March 2024 in the British Medical Journal , which found that women who had used the Pfizer contraceptive injection Depo-Provera 1 for more than one year were 5.6 times more likely to develop an intracranial meningioma, a type of brain tumor.
  • An estimated 74 million women globally receive Depo-Provera injections according to a 2019 UN study 2 .

A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States Courthouse is Pensacola, Florida. The litigation is being brought on behalf of women in the USA who developed meningiomas after receiving at least 4 consecutive injections of Pfizer's Depo-Provera (DMPA). One of the law firms appointed to the Plaintiff's Executive Committee responsible for overseeing the MDL is Levin Papantonio, which has helped to secure more than $80 billion in jury verdicts and settlements against some of the world's largest corporations, including Johnson & Johnson, BP, Dupont, 3M, Merck and big tobacco. The law firm is currently acting for plaintiffs in the Talcum Powder Litigation against Johnson & Johnson and the Preterm Infant Nutrition Products Liability Litigation against Abbott Laboratories and Mead Johnson, owned by Reckitt Benckiser.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

  • Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
  • After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT
  • XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer
  • Data continue to show wide-ranging effect of treatment with XTANDI (enzalutamide) plus ADT across various patient subgroups, notably those with high-volume disease, no prior docetaxel use, and synchronous disease
  • Long-term data reinforce XTANDI (enzalutamide) plus ADT as a standard of care

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura "Astellas") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES ( NCT02677896 ) study, reporting a five-year follow up of overall survival (OS) benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI ™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen deprivation therapy (ADT) compared to placebo plus ADT. These data will be presented during an oral presentation (Abstract #5005) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago ( Tuesday, June 3 9:45 a.m.- 12:45 p.m. US CT).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines. 3SBio plans to initiate the first Phase 3 study in China in 2025.

Under the terms of the agreement, 3SBio and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd. will grant Pfizer an exclusive global license to develop, manufacture and commercialize SSGJ-707 worldwide, excluding China. The agreement also provides Pfizer the option of commercialization rights in China. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion as well as tiered double-digit royalties on sales of SSGJ-707, if approved.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less

Latest Press Releases

Related News

×